Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Chief Business Officer | January 16, 2024 | January 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date January 16, 2024 · Filed January 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 136,748 |
Ending reported balance
After 2024-01-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-16 · Exercise / conversion · Acquired 18,000 · Balance 154,748 F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Row 2 · 2024-01-16 · Sale · Disposed 18,000 · Balance 136,748 F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2030-03-03 | Direct | 361,469 |
Reported balance
After 2024-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-16 · Exercise / conversion · Disposed 18,000 · Balance 361,469 F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 212,507 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 212,507 F2: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 80,450 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 80,450 F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 5,436 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 5,436 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
F2: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F3: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2023 Filed Jan 19, 2023 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-004043 · doc4.xml · derivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,955 Underlying: Class A Common Stock · 5,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 10,000 | $9.16 | $91,561.00 |
DisclosureSEC source: 0001209191-23-004043 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,160 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.92 to $9.33 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.22 | $11,100.00 |
DisclosureSEC source: 0001209191-23-004043 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 22:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-22-061999 · doc4.xml · derivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641,955 Underlying: Class A Common Stock · 5,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 22:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 10,000 | $8.85 | $88,525.00 |
DisclosureSEC source: 0001209191-22-061999 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,160 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.54 to $9.14 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 22:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.22 | $11,100.00 |
DisclosureSEC source: 0001209191-22-061999 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-22-057708 · doc4.xml · derivative · entry 5 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,955 Underlying: Class A Common Stock · 5,000 shares Expires 2030-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 4,941 | $11.92 | $58,873.50 |
DisclosureSEC source: 0001209191-22-057708 · doc4.xml · nonDerivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,160 F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.34 to $12.32 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 5,059 | $12.70 | $64,249.30 |
DisclosureSEC source: 0001209191-22-057708 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,101 F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.22 | $11,100.00 |
DisclosureSEC source: 0001209191-22-057708 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 613 | $11.86 | $7,270.18 |
DisclosureSEC source: 0001209191-22-057708 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,160 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-22-053981 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,955 Underlying: Class A Common Stock · 5,000 shares Expires 2030-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 5,000 | $10.63 | $53,129.50 |
DisclosureSEC source: 0001209191-22-053981 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,773 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.44 to $11.36 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 5,000 | $11.21 | $56,050.00 |
DisclosureSEC source: 0001209191-22-053981 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,773 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.22 | $11,100.00 |
DisclosureSEC source: 0001209191-22-053981 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 22:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-22-050400 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,955 Underlying: Class A Common Stock · 5,000 shares Expires 2030-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 22:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 400 | $13.97 | $5,589.00 |
DisclosureSEC source: 0001209191-22-050400 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,773 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.93 to $14.07 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 22:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 9,600 | $13.34 | $128,045.76 |
DisclosureSEC source: 0001209191-22-050400 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,173 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.89 to $13.82 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 22:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.22 | $11,100.00 |
DisclosureSEC source: 0001209191-22-050400 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-22-046464 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,955 Underlying: Class A Common Stock · 25,000 shares Expires 2030-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $12.61 | $378,444.00 |
DisclosureSEC source: 0001209191-22-046464 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,773 F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.06 to $12.96 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 25,000 | $2.22 | $55,500.00 |
DisclosureSEC source: 0001209191-22-046464 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 613 | $12.96 | $7,944.48 |
DisclosureSEC source: 0001209191-22-046464 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,773 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| May 16, 2022 Filed May 18, 2022 23:20 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 870 | $5.67 | $4,932.90 |
DisclosureSEC source: 0001209191-22-030257 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,386 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 5,436 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007918 · doc4.xml · derivative · entry 5 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,436 Underlying: Class A Common Stock · 5,436 shares Expires 2032-02-04 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 80,450 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007918 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,450 Underlying: Class A Common Stock · 80,450 shares Expires 2032-02-04 F4 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,114 | $11.40 | $12,699.60 |
DisclosureSEC source: 0001209191-22-007918 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,256 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007918 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,370 F3 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 40,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007918 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,652 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter. F2 · balance_after: Includes 382 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,045 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-038174 · doc4.xml · derivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,955 Underlying: Class A Common Stock · 45,045 shares Expires 2030-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 45,045 | $2.22 | $99,999.90 |
DisclosureSEC source: 0001209191-21-038174 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 732,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-028049 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,000 Underlying: Class A Common Stock · 732,000 shares Expires 2030-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 732,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-028049 · doc4.xml · derivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 732,000 shares Expires 2030-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028049 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028049 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.